Obsidian Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Obsidian Therapeutics's estimated annual revenue is currently $18.1M per year.(i)
  • Obsidian Therapeutics's estimated revenue per employee is $177,794
  • Obsidian Therapeutics's total funding is $164.5M.

Employee Data

  • Obsidian Therapeutics has 102 Employees.(i)
  • Obsidian Therapeutics grew their employee count by 16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients. We create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs. With this unique approach, we can dramatically improve on the current generation of cell therapies. Headquartered in Cambridge, MA, Obsidian has assembled an industry-leading team of experts in immunology, cell therapy, and oncology. We continue to build our team so please check our website (www.obsidiantx.com) often for job opportunities.

keywords:Healthcare,Human Resources Hr,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Obsidian Therapeutics's People

Senior ScientistReveal Email/Phone
SVP, Program Planning & DevelopmentReveal Email/Phone
Associate DirectorReveal Email/Phone
ScientistReveal Email/Phone
Senior Associate ScientistReveal Email/Phone
VP, Analytical DevelopmentReveal Email/Phone
Director Process DevelopmentReveal Email/Phone
Senior Director, Head Cell TherapyReveal Email/Phone
ScientistReveal Email/Phone
Senior ScientistReveal Email/Phone

Obsidian Therapeutics News

2022-04-13 - Obsidian Therapeutics to Present Preclinical Data from cytoTIL15 ...

Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting...

2021-09-09 - Obsidian Therapeutics : Announces Closing of $115 Million Series B Financing

CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover ...

2021-09-09 - Obsidian Therapeutics, Inc. announced that it has received $115 million in funding from a group of investors

Obsidian Therapeutics, Inc. announced that it has raised $115 million in a round of funding led by new investor TTCG Crossover Management, LLC on September 9, 2021. The transaction included participation form Vertex Pharmaceuticals Incorporated, new investors RA Capital Management, L.P, Citadel ...

2021-09-09 - Obsidian Therapeutics Closes $115M Series B Financing

Obsidian Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies, closed a $115m Series B financing. The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel co ...

2019-09-08 - Obsidian Therapeutics Announces Strengthening of Executive ...

CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Obsidian Therapeutics Executives

Ryan DawsChief Financial Officer
Gary VanasseSVP, Chief Medical Officer
Jan MeulenChief Scientific Officer
Paul WottonCEO, Board Member
Lee GiguereChief Legal Officer
Jennifer PetersonChief People Officer
David McGrathChief Scientific Officer
Shyam SubramanianChief Technical Officer
Jennifer OhdeChief Medical Officer
Gary VanasseSVP, Chief Medical Officer
Karen BrownSenior Vice President, Intellectual Property and Legal Affairs
Melanie CallVice President, Head of Program Management
Prakash PrabhakarVice President, Clinical Operations & Translational Early Clinical Development
Nic BettsVice President of IT and Facilities
Nicole HsuVice President Regulatory Affairs
David AubuchonVice President Finance
Kirsten KesterSenior Vice President, Business Development
Parnian Zia-AmirhosseiniVP, Regulatory Affairs & QA